{"id":4253,"date":"2008-09-26T08:32:42","date_gmt":"2008-09-26T12:32:42","guid":{"rendered":"http:\/\/piel-l.org\/blog\/?p=4253"},"modified":"2008-09-27T08:32:55","modified_gmt":"2008-09-27T12:32:55","slug":"toxina-botulinica-reacciones-anafilacticas","status":"publish","type":"post","link":"https:\/\/piel-l.org\/blog\/4253","title":{"rendered":"Toxina Botul\u00ednica \u00bfreacciones anafil\u00e1cticas?"},"content":{"rendered":"<p><em><strong>Enviada cordialmente por el Dr. Rolando Hern\u00e1ndez<\/strong><\/em><\/p>\n<ul>\n<li>Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection<\/li>\n<li>Fatal case of BOTOX-related anaphylaxis?<\/li>\n<li>Botulinum toxin therapy in the ovalbumin-sensitized rat<\/li>\n<\/ul>\n<p><!--more--><\/p>\n<p><strong>Idiosyncratic  adverse reactions to intramuscular botulinum toxin type A injection.<\/strong><\/p>\n<p><strong>LeWitt PA<\/strong>, <strong>Trosch RM<\/strong>.<\/p>\n<p>Clinical Neuroscience Center, Sinai Hospital, West Bloomfield, Michigan,  USA.<\/p>\n<p>Three cases of adverse reactions to repeated intramuscular botulinum  toxin A (BTA) injections are described: a persistent rash on the face  at the site of injection, a localized anaphylactic reaction following  BTA injection into one leg, and bilateral ptosis repeatedly following  BTA injection into neck muscles. The mechanisms for these idiosyncratic  adverse responses are not known.<\/p>\n<p>Mov Disord. 1997 Nov;12(6):1064-7.<br \/>\n <strong>Fatal  case of BOTOX-related anaphylaxis?<\/strong><\/p>\n<p><strong>Li M<\/strong>, <strong>Goldberger BA<\/strong>, <strong>Hopkins C<\/strong>.<\/p>\n<p>Department of Pathology, Immunology and Laboratory Medicine, University  of Florida College of Medicine, Gainesville, FL 32610-0275, USA.<\/p>\n<p>Anaphylactic drug reactions are rare and often serious events. The Botulinum  toxin A, marketed as BOTOX, was recently approved by the Food and Drug  Administration for cervical dystonia and glabellar wrinkles, after its  approved use and success with blepharospasm, strabismus, and disorders  of the 7th cranial nerve. It has been well received due to its efficacy  in improving facial lines. This case report documents the first death  associated with a Botox-lidocaine mixture given to a woman for chronic  neck and back pain. Based on the medical records, autopsy, and laboratory  findings, the cause of death was determined to be anaphylaxis to the  Botox-lidocaine mixture. The history, indications, off-label uses and  possible future applications of Botox are reviewed as well as the uses  and complications of lidocaine. Although the anaphylaxis cannot be definitively  proven to be due to Botox alone, this case warns of an adverse reaction  related to Botox, a drug that is rapidly expanding in range of use as  well as increased usage.<\/p>\n<p>J Forensic  Sci. 2005 Jan;50(1):169-72.<\/p>\n<p><strong>Botulinum  toxin therapy in the ovalbumin-sensitized rat.<\/strong><\/p>\n<p><strong>Wen WD<\/strong>, <strong>Yuan F<\/strong>, <strong>Wang JL<\/strong>, <strong>Hou YP<\/strong>.<\/p>\n<p>School of Life Science, Lanzhou University, Lanzhou, PR China.<\/p>\n<p>OBJECTIVE: The aim of this study was to determine whether intranasal  administration of botulinum toxin type A (BTX-A) could relieve the typical  symptoms of allergic rhinitis (AR) and alter substance P (SP)- and vasoactive  intestinal peptide (VIP)-immunoreactive (IR) expression in nasal mucosa  of AR animals sensitized with ovalbumin (OVA). METHODS: AR was induced  by intraperitoneal injection of OVA followed by its repeated intranasal  instillation in female Wistar rats. Some AR animals were intranasally  treated with a cotton strip containing BTX-A (10 U per nostril) for  1 h. After BTX-A treatment, OVA was repeatedly instilled in AR and AR  + BTX-A groups every 2 days for 10 days. Subsequently, nasal symptoms  were evaluated, and nasal secretions collected. Finally, the nasal mucosae  of all animals were prepared for histological and immunohistochemical  assessment. RESULTS: BTX-A administration alleviated typical AR symptoms  including rhinorrhea, nasal itching and sneezing, and subsequent intranasal  repeated challenge with OVA did not trigger AR symptoms. After BTX-A  treatment, inflammatory histological characteristics within the nasal  mucosa of AR animals were absent, but atrophy of serous glands was observed.  BTX-A decreased dense SP-IR and VIP-IR cells and fibers within and beneath  the epithelium, around blood vessels and close to serous glands in AR  animals. CONCLUSION: Local BTX-A treatment is an effective method to  reduce AR symptoms. BTX-A decreased the excessive SP-IR and VIP-IR expression  induced by OVA. Therefore, BTX-A may affect the nasal mucosa via the  suppression of neuropeptides, playing a major role in autonomous mucosal  innervation in the pathophysiology of AR. Copyright (c) 2007 S. Karger  AG, Basel.<\/p>\n<p>Neuroimmunomodulation.  2007;14(2):78-83. Epub 2007 Aug 21.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Enviada cordialmente por el Dr. Rolando Hern\u00e1ndez Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection Fatal case of BOTOX-related anaphylaxis? Botulinum toxin therapy in the ovalbumin-sensitized rat<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"class_list":["post-4253","post","type-post","status-publish","format-standard","","category-farmacologia"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/4253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=4253"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/4253\/revisions"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=4253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=4253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=4253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}